Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$14.52 - $22.46 $1.36 Million - $2.1 Million
-93,700 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$16.57 - $21.08 $140,994 - $179,369
-8,509 Reduced 8.33%
93,700 $1.91 Million
Q4 2020

Feb 02, 2021

SELL
$14.89 - $20.16 $29,780 - $40,320
-2,000 Reduced 1.92%
102,209 $1.82 Million
Q3 2020

Nov 05, 2020

BUY
$14.79 - $22.49 $16,949 - $25,773
1,146 Added 1.11%
104,209 $1.54 Million
Q2 2020

Aug 12, 2020

BUY
$20.64 - $30.69 $30,010 - $44,623
1,454 Added 1.43%
103,063 $2.16 Million
Q1 2020

May 12, 2020

BUY
$17.84 - $31.21 $17,608 - $30,804
987 Added 0.98%
101,609 $2.35 Million
Q4 2019

Jan 27, 2020

BUY
$16.12 - $25.89 $300,734 - $483,003
18,656 Added 22.76%
100,622 $2.61 Million
Q3 2019

Oct 31, 2019

BUY
$16.51 - $23.78 $317,834 - $457,788
19,251 Added 30.7%
81,966 $1.6 Million
Q2 2019

Aug 15, 2019

BUY
$15.6 - $25.15 $117,234 - $189,002
7,515 Added 13.61%
62,715 $1.02 Million
Q1 2019

May 03, 2019

SELL
$22.57 - $28.15 $33,855 - $42,225
-1,500 Reduced 2.65%
55,200 $1.25 Million
Q4 2018

Feb 08, 2019

SELL
$22.52 - $35.07 $123,860 - $192,885
-5,500 Reduced 8.84%
56,700 $1.45 Million
Q3 2018

Nov 13, 2018

SELL
$22.83 - $32.67 $116,432 - $166,617
-5,100 Reduced 7.58%
62,200 $2.03 Million
Q2 2018

Aug 15, 2018

SELL
$22.06 - $25.52 $134,566 - $155,672
-6,100 Reduced 8.31%
67,300 $1.53 Million
Q1 2018

May 11, 2018

SELL
$23.37 - $29.71 $84,132 - $106,956
-3,600 Reduced 4.68%
73,400 $1.78 Million
Q4 2017

Feb 06, 2018

BUY
$25.82 - $35.66 $46,476 - $64,187
1,800 Added 2.39%
77,000 $2.15 Million
Q3 2017

Nov 15, 2017

BUY
$23.88 - $34.96 $1.8 Million - $2.63 Million
75,200
75,200 $2.58 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $640M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.